S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024

Syndax Pharmaceuticals (SNDX) Short Interest Ratio & Short Volume

$23.88
-0.53 (-2.17%)
(As of 02/28/2024 ET)

Syndax Pharmaceuticals Short Interest Data

Current Short Volume
8,600,000 shares
Previous Short Volume
8,690,000 shares
Change Vs. Previous Month
-1.04%
Dollar Volume Sold Short
$194.96 million
Short Interest Ratio / Days to Cover
5.8
Last Record Date
February 15, 2024
Outstanding Shares
84,810,000 shares
Percentage of Shares Shorted
10.14%
Today's Trading Volume
1,193,436 shares
Average Trading Volume
1,161,583 shares
Today's Volume Vs. Average
103%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Syndax Pharmaceuticals ?

Sign up to receive the latest short interest report for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

SNDX Short Interest Over Time

SNDX Days to Cover Over Time

SNDX Percentage of Float Shorted Over Time


Syndax Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/15/20248,600,000 shares $194.96 million -1.0%N/A5.8 $22.67
1/31/20248,690,000 shares $178.06 million No ChangeN/A5.8 $20.49
1/15/20248,690,000 shares $193.27 million +3.7%N/A5.4 $22.24
12/31/20238,380,000 shares $181.09 million -19.0%N/A4.7 $21.61
12/15/202310,340,000 shares $214.76 million +1.1%N/A4.8 $20.77
11/30/202310,230,000 shares $170.28 million -3.7%N/A5.4 $16.65
11/15/202310,620,000 shares $159.94 million +6.4%N/A6.2 $15.06
10/31/20239,980,000 shares $140.52 million +17.4%N/A6.1 $14.08
10/15/20238,500,000 shares $101.92 million +12.1%N/A5.7 $11.99
9/30/20237,580,000 shares $110.06 million -0.1%N/A6 $14.52
9/15/20237,590,000 shares $131.76 million +9.1%N/A9.8 $17.36
8/31/20236,960,000 shares $128.83 million -2.8%N/A8.8 $18.51
8/15/20237,160,000 shares $132.03 million +7.7%N/A8.4 $18.44
7/31/20236,650,000 shares $141.78 million +12.1%N/A7.4 $21.32
7/15/20235,930,000 shares $125.42 million +3.3%N/A6.8 $21.15
6/30/20235,740,000 shares $120.14 million +2.5%N/A6.5 $20.93
6/15/20235,600,000 shares $119.45 million -10.0%N/A5.9 $21.33
5/31/20236,220,000 shares $124.21 million -2.7%N/A6.7 $19.97
5/15/20236,390,000 shares $135.15 million -2.0%N/A7.4 $21.15
4/30/20236,520,000 shares $133.99 million -5.2%N/A7.9 $20.55
4/15/20236,880,000 shares $137.60 million -9.8%N/A8.6 $20.00
3/31/20237,630,000 shares $161.15 million +12.4%N/A9.5 $21.12
3/15/20236,790,000 shares $151.42 million +13.4%N/A8.9 $22.30
2/28/20235,990,000 shares $151.85 million +8.5%N/A7 $25.35
2/15/20235,520,000 shares $143.46 million +0.6%N/A6.8 $25.99
1/31/20235,490,000 shares $157.56 million +0.6%N/A6.5 $28.70
1/15/20235,460,000 shares $143.65 million -14.3%N/A6.4 $26.31
12/30/20226,370,000 shares $162.12 million +22.5%N/A7.3 $25.45
12/15/20225,200,000 shares $125.84 million +17.7%N/A6.1 $24.20
11/30/20224,420,000 shares $105.90 million +5.7%N/A5.8 $23.96
11/15/20224,180,000 shares $91.46 million +2.7%N/A6 $21.88
10/31/20224,070,000 shares $93.45 million -9.2%N/A5.9 $22.96
10/15/20224,480,000 shares $105.41 million +0.9%9.4%6.7 $23.53
9/30/20224,440,000 shares $106.69 million -3.5%9.3%6.7 $24.03
9/15/20224,600,000 shares $113.02 million No Change9.6%7.2 $24.57
8/31/20224,600,000 shares $108.61 million +0.4%9.7%7 $23.61
8/15/20224,580,000 shares $113.31 million +5.1%9.6%7.1 $24.74
7/31/20224,360,000 shares $88.81 million +2.6%9.2%6.6 $20.37
7/15/20224,250,000 shares $80.92 million -24.8%9.2%6.8 $19.04
6/30/20225,650,000 shares $108.71 million -4.2%12.3%9.6 $19.24













SNDX Short Interest - Frequently Asked Questions

What is Syndax Pharmaceuticals' current short interest?

Short interest is the volume of Syndax Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 15th, investors have sold 8,600,000 shares of SNDX short. Learn More on Syndax Pharmaceuticals' current short interest.

What is a good short interest ratio for Syndax Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SNDX shares currently have a short interest ratio of 6.0. Learn More on Syndax Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Syndax Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Syndax Pharmaceuticals: GTS Securities LLC, Frazier Life Sciences Management L.P., Citadel Advisors LLC, Worth Venture Partners LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Syndax Pharmaceuticals' short interest increasing or decreasing?

Syndax Pharmaceuticals saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 8,600,000 shares, a decline of 1.0% from the previous total of 8,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Syndax Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Syndax Pharmaceuticals: Maravai LifeSciences Holdings, Inc. (5.82%), Alpine Immune Sciences, Inc. (6.94%), TG Therapeutics, Inc. (26.23%), Structure Therapeutics Inc. (8.70%), PTC Therapeutics, Inc. (13.76%), NewAmsterdam Pharma (0.82%), Agios Pharmaceuticals, Inc. (13.97%), Zai Lab Limited (4.75%), Morphic Holding, Inc. (11.79%), Harmony Biosciences Holdings, Inc. (20.32%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Super Micro Computer, Inc. ($5.32 billion), T-Mobile US, Inc. ($4.38 billion), General Motors ($3.76 billion), Occidental Petroleum Co. ($3.08 billion), Charter Communications, Inc. ($2.65 billion), Coinbase Global, Inc. ($2.62 billion), Tractor Supply ($2.52 billion), Moderna, Inc. ($2.19 billion), Rivian Automotive, Inc. ($1.84 billion), and Royal Caribbean Cruises Ltd. ($1.78 billion). View all of the most shorted stocks.

What does it mean to sell short Syndax Pharmaceuticals stock?

Short selling SNDX is an investing strategy that aims to generate trading profit from Syndax Pharmaceuticals as its price is falling. SNDX shares are trading down $0.53 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Syndax Pharmaceuticals?

A short squeeze for Syndax Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SNDX, which in turn drives the price of the stock up even further.

How often is Syndax Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNDX, twice per month. The most recent reporting period available is February, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:SNDX) was last updated on 2/29/2024 by MarketBeat.com Staff